



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/17, G01N 33/48, A01K 67/027</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/27948</b> <b>(43) International Publication Date:</b> 10 June 1999 (10.06.99)
<b>(21) International Application Number:</b> PCT/CA98/01105 <b>(22) International Filing Date:</b> 27 November 1998 (27.11.98) <b>(30) Priority Data:</b> 2,223,225 28 November 1997 (28.11.97) CA <b>(71) Applicant (for all designated States except US):</b> CANADIAN BLOOD SERVICES [CA/CA]; 1800 Alta Vista Drive, Ottawa, Ontario K1G 4J5 (CA). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAZARUS, Alan, H. [CA/CA]; Suite 1705, 49 Thorncliffe Park Drive, Toronto, Ontario M4H 1J6 (CA). CROW, Andrew, R. [CA/CA]; Suite 1217, 1 Massey Square, East York, Ontario M4C 5L4 (CA). FREEDMAN, John [CA/CA]; Suite 4405, 44 Charles Street West, Toronto, Ontario M4Y 1R8 (CA). <b>(74) Agents:</b> CÔTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> USE OF A SOLUBLE RECOMBINANT HUMAN CD40L PROTEIN FOR INHIBITING <i>IN VIVO</i> IMMUNE RESPONSE		
<b>(57) Abstract</b>  The invention relates to a method for inhibiting <i>in vivo</i> immune response and to the use of a soluble recombinant human CD40L or a sequence within said soluble recombinant human CD40L containing the active binding site with CD40 for inhibiting an immune response. The invention also relates to a mouse model of human alloimmunization for testing <i>in vivo</i> effects of an immunotherapy or inhibition of a human antibody response.		